search
Back to results

A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma (BRIM8)

Primary Purpose

Melanoma

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Vemurafenib
Placebo
Sponsored by
Hoffmann-La Roche
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Melanoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histologically confirmed melanoma of cutaneous origin
  • Participants with BRAFV600 mutation-positive, cutaneous melanoma (either pathologic Stage IIC or Stage III according to AJCC Staging Criteria version 7 that has been completely resected
  • BRAF V600 mutation status of the current primary tumor or involved lymph node determined to be positive using the cobas BRAF V600 mutation test
  • Surgically rendered free of disease within 90 days of randomization
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Life expectancy of at least 5 years
  • Fully recovered from the effects of any major surgery or significant traumatic injury prior to the first dose of study treatment
  • Adequate hematologic, hepatic, and renal function

Exclusion Criteria:

  • History of any systemic or local therapy (e.g., chemotherapy, biologic or targeted therapy, hormonal therapy, or photodynamic therapy) for the treatment or prevention of melanoma, including interferon alpha-2b and pegylated interferon alpha-2b
  • History of limb perfusion therapy
  • History of radiotherapy for the treatment of melanoma
  • Invasive malignancy other than melanoma at the time of enrollment or within 5 years prior to first dose of study treatment
  • Family history of inherited colon cancer syndromes
  • Known personal history of >3 adenomatous colorectal polyps or a personal history of adenomatous colorectal polyp(s) >2 centimeters (cm) in size
  • History of or current clinical, radiographic, or pathologic evidence of in-transit metastases, satellite, or microsatellite lesions
  • History of or current clinical, radiographic, or pathologic evidence of recurrent lymph node involvement after resection of a primary melanoma with lymph node involvement at any time in the past
  • History of local and/or regional and/or distant melanoma recurrence
  • History or current radiographic or pathologic evidence of distant metastases
  • History of clinically significant cardiac or pulmonary dysfunction
  • Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study treatment
  • Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus

Sites / Locations

  • University of Alabama at Birmingham
  • UCLA Department of Medicine; Division of Hematology / Oncology
  • Kaiser Permanente - Hayward
  • UCLA Hematology Oncology - Irvine
  • UCSD Moores Cancer Center
  • The Angeles Clinic and Research Institute - W LA Office
  • Cancer Center Of Santa Barbara; Network Clinical Research Specialist
  • TRIO-US Network Administration; Network Clinical Research Specialist
  • Kaiser Foundation Hospital - Oakland (W. MacArthur)
  • Kaiser Permanente - Oakland
  • UCLA Healthcare/Pasadena Oncology
  • Kaiser Permanente - Roseville
  • Kaiser Permanente Sacramento Medical Center
  • Kaiser Permanente
  • K. Permanente - San Jose
  • Coastal Integrative Cancer Care
  • Kaiser Permanente - Santa Clara
  • Kaiser Permanente - South San Francisco
  • Stanford University School of Medicine; Stanford Hospital Pharmacy
  • UCLA Cancer Center Hema/Oncol
  • Kaiser Permanente - Vallejo
  • Kaiser Permanente - Walnut Creek
  • UCLA Hematology Oncology - Westlake
  • University Of Colorado
  • St. Mary's Hospital Regional Cancer Center
  • Florida Cancer Specialists - Broadway
  • Memorial Healthcare System
  • GulfCoast Oncology
  • Oncology Specialists, S.C.
  • Indiana University Health; Goshen Center for Cancer Care
  • Indiana University Department of Medicine; Division of Infectious Diseases
  • U of L - Physicians Pulmonology; Dept of Neuroradiology and Dept of Diagnostic Radiology
  • Barbara Ann Karmanos Cancer Institute
  • St. Luke's Hospital
  • University of Kansas Medical Center; Cancer Center
  • Washington University; Dept of Medicine/Div of Medical Oncology
  • Atlantic Health Systems; Pediatrics
  • New York University Medical Center PRIME; NYU Clinical Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • Duke University Medical Center; Oncology
  • University of Pennsylvania Health System
  • MUSC Hollings Cancer Center/cannon Park Place; Attn: Tamara Saunders
  • West Clinic
  • Tennessee Oncology PLLC - Nashville (20th Ave)
  • Vanderbilt University Medical Center
  • MD Anderson Cancer Center
  • Mary Babb Randolph Cancer Center
  • Fundación CIDEA
  • Instituto Medico Especializado Alexander Fleming
  • Hospital Britanico de Buenos Aires
  • Hospital Universitario Austral
  • Centro de Investigacion Pergamino SA
  • Instituto de Oncología de Rosario
  • ISIS Clinica Especializada
  • Chris O'Brien Lifehouse
  • Melanoma Institute Australia
  • Calvary Mater Newcastle
  • Border Medical Oncology
  • Southern Medical Day Care Centre
  • Cairns Base Hospital
  • The Townsville Hospital; Townsville Cancer Centre
  • Royal Adelaide Hospital; Hepatology
  • Queen Elizabeth Hospital
  • Launceston General Hospital; Gastroenterology Research
  • Box Hill Hospital
  • Peninsula Oncology Centre; Frankston Private
  • Peter Maccallum Cancer Centre
  • Alfred Hospital
  • Fiona Stanley Hospital
  • Medizinische Universität Innsbruck
  • Klinikum Wels-Grieskirchen
  • Krankenanstalt Rudolfstiftung Wien
  • Medizinische Universität Wien
  • ZNA Middelheim
  • Institut Jules Bordet
  • UZ Antwerpen
  • UZ Gent
  • Jessa Zkh (Campus Virga Jesse)
  • AZ Groeninge, Apotheek
  • Trymed Clinical Research
  • Hospital de Caridade de Ijuí
  • CITO - Centro Integrado de Terapia Onco-Hematológica - Hospital da Cidade de Passo Fundo
  • Hospital das Clinicas - UFRGS
  • Clinica de Oncologia de Porto Alegre - CliniOnco
  • Hospital Sírio-Libanês
  • BC Cancer Agency Vancouver Centre - PARENT; BC Cancer Agency
  • Saint Boniface General Hospital; Section of Nephrology BG 007
  • Saint John Regional Hospital; Department of Oncology
  • LHSC - Victoria Hospital; Department of Pediatrics
  • The Ottawa Hospital Cancer Center; General Campus
  • Toronto Sunnybrook Hospital
  • Princess Margaret Hospital; Department of Med Oncology
  • CHUM Hôpital Notre-Dame
  • Mcgill University - Royal Victoria Hospital; Oncology
  • CHUQ - Hôtel-Dieu de Québec
  • General Hospital Pula
  • General Hospital Varazdin
  • Clinical Hospital Center Sestre Milosrdnice
  • Clinical Hospital Centre Zagreb
  • Masarykuv onkologicky ustav
  • Fakultni nemocnice Hradec Kralove
  • Fakultní nemocnice Olomouc
  • Fakultni nemocnice Ostrava
  • Nemocnice Na Bulovce
  • Vseobecna fakultni nemocnice v Praze
  • Fakultni nemocnice Kralovske Vinohrady
  • East Tallinn Central Hospital; Clinic of Internal Medicine
  • North Estonia Medical Centre Foundation
  • Tartu University Hospital; Clinic of Hematology and Oncology
  • CHU Besançon - Hôpital Jean Minjoz
  • Groupe Hospitalier Saint André - Hôpital Saint André
  • Hôpital Ambroise Paré - Boulogne-Billancourt; Respiratory
  • Hopital Claude Huriez - CHU Lille
  • Hopital de la Timone
  • CHU NANTES - Hôtel Dieu; Pharmacy
  • CHU Nice - Hopital de l'Archet 2
  • Hôpital Saint-Louis
  • Centre Hospitalier Lyon Sud
  • CHU de Rouen Hopital; Service de Neurologie
  • CHU de Toulouse - Hôpital Larrey
  • St. Josef-Hospital Universitaetsklinikum
  • Elbekliniken Buxtehude GmbH
  • Universitätsklinikum Essen
  • Universitaetsklinikum Frankfurt
  • Universitätsklinikum Heidelberg
  • Universitaetsklinikum Schleswig-Holstein - Campus Kiel; Klinik fuer Allgemeine Innere Medizin
  • Universitätsklinikum Koeln
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz; Apotheke
  • Klinikum Mannheim GmbH Universitätsklinikum
  • Fachklinik Hornheide
  • Universitätsklinikum Tübingen
  • Universitätsklinikum Wurzburg
  • Cork University Hospital
  • Mater Private Hospital
  • The Mater Misericordiae Hospital
  • University College Hospital
  • Soroka Medical Center
  • Rambam Health Care Campus
  • Hadassah University Hospital - Ein Kerem
  • Rabin Medical Center-Beilinson Campus
  • Chaim Sheba Medical Center
  • Tel-Aviv Sourasky Medical Center
  • Istituto Nazionale Tumori Fondazione G. Pascale
  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata
  • Istituto Nazionale Tumori Regina Elena IRCCS
  • IDI-Istituto Dermopatico dell'Immacolata IRCCS
  • Istituto Nazionale per la Ricerca sul Cancro di Genova
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
  • Asst Degli Spedali Civili Di Brescia
  • Ospedale San Raffaele
  • Istituto Europeo Di Oncologia
  • IRCCS Istituto Clinico Humanitas; Farmacia
  • Istituto Tumori Giovanni Paolo II IRCSS; Ospedale Oncologico Bari
  • A.O.U. Senese Policlinico Santa Maria Alle Scotte
  • IOV - Istituto Oncologico Veneto IRCCS
  • Centro Oncologico Belenus
  • Hospital Civil de Guadalajara Fray Antonio Alcalde
  • Centro Regiomontano de Investigación Clínica
  • Sanatorio la Luz
  • Universitair Medisch Centrum Groningen
  • Leids Universitair Medisch Centrum; Cardiology
  • Christchurch Hospital NZ
  • Wellington Hospital
  • Stavanger Universitetssykehus, Helse Stavanger HF
  • SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie
  • Przychodnia Med-Polonia Sp. z o.o.
  • Centrum Onkologii- Instytut; im. M.Skłodowskiej-Curie
  • Dolnoslaskie Centrum Onkologii
  • IPO de Coimbra; Servico de Oncologia Medica
  • Hospital do Espirito Santo; Servico de Oncologia Medica
  • Hospital de Santa Maria; Servico de Oncologia Medica
  • IPO do Porto; Servico de Oncologia Medica
  • Moscow City Oncology Hospital #62
  • Krasnodar City Oncology Center
  • FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
  • Scientific Research Oncology Institute named after N.N. Petrov
  • Institute of Oncology and Radiology of Serbia
  • Military Medical Academy
  • Clinical Center Bezanijska Kosa
  • Institute for oncology of Vojvodina
  • GVI Rondebosch Oncology Centre
  • Mary Potter Oncology Centre
  • Groote Schuur Hospital Radiation Oncology Department; Department of Radiation Oncology
  • University of Pretoria Oncology Department
  • Sandton Oncology Medical Group
  • Hospital Clinico Universitario de Santiago
  • Hospital Costa del Sol; Servicio de Oncologia
  • Hospital de la Santa Creu; i Sant Pau
  • Institut Catala d Oncologia Hospital Duran i Reynals
  • Hospital General Universitario Gregorio Marañon
  • Hospital Universitari i Politecnic La Fe
  • Länssjukhuset Ryhov
  • Norrlands Universitetssjukhus
  • Centrallasarettet Växjö
  • CHUV; Departement d'Oncologie
  • CI Dnipropetrovsk CMCH 4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU
  • Lviv State Oncological Regional Treatment and Diagnostic Center
  • Bristol Haematology and Oncology Centre
  • Addenbrooke's Hospital
  • Velindre Cancer Centre
  • Western General Hospital
  • Queen Elizabeth Hospital
  • Guys and St Thomas NHS Foundation Trust, Guys Hospital
  • Nottingham University Hospitals City Campus
  • Churchill Hospital
  • Royal Cornwall Hospital
  • New Cross Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

Cohort 1 Vemurafenib

Cohort 1 Placebo

Cohort 2 Vemurafenib

Cohort 2 Placebo

Arm Description

Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 milligrams (mg) twice daily, in 28-day cycles, for up to 52 weeks

Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks

Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks

Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks

Outcomes

Primary Outcome Measures

Disease-Free Survival (DFS) as Assessed Using Contrast-Enhanced Magnetic Resonance Imaging (MRI) or Contrast Enhanced Computed Tomography (CT)
DFS was defined as the time from randomization until the date of the first local, regional, or distant melanoma recurrence, occurrence of new primary melanoma, or death from any cause.

Secondary Outcome Measures

Distant Metastasis-Free Survival (DMFS) as Assessed Using Contrast-Enhanced MRI or Contrast Enhanced CT
DMFS was defined as the time from randomization until the date of diagnosis of distant (i.e. non-locoregional) metastases or death from any cause.
Overall Survival (OS)
OS is defined as the time from randomization until the date of death from any cause.
Percentage of Participants With Adverse Events
An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) 30-Item Quality of Life Questionnaire (QLQ-C30) Score
European Organisation for Research and Treatment of Cancer 30-Item Quality of Life Questionnaire assesses 8 symptoms, function, financial difficulties, and a global health status/health-related quality of life (HRQoL). Most questions use a 4-point scale (1 'Not at all' to 4 'Very much';2 questions use a 7-point scale (1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. Higher scores for the function and HRQoL represent higher levels of functioning and HRQoL, higher scores for the symptom represent higher levels of symptoms/problems, higher score for financial difficulty represent higher level of perceived financial burden of treatment. Changes of 5-10 points are considered to represent a minimally important difference to participants. A positive value means an increase, and negative value means a decrease in score at the indicated time-point relative to the score at baseline (Cycle 1 Day 1).
Plasma Concentration of Vemurafenib

Full Information

First Posted
August 15, 2012
Last Updated
July 11, 2019
Sponsor
Hoffmann-La Roche
search

1. Study Identification

Unique Protocol Identification Number
NCT01667419
Brief Title
A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma
Acronym
BRIM8
Official Title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
September 24, 2012 (Actual)
Primary Completion Date
June 23, 2017 (Actual)
Study Completion Date
July 13, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche

4. Oversight

5. Study Description

Brief Summary
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in participants with completely resected, cutaneous BRAF mutation-positive melanoma at high risk for recurrence. Participants will be enrolled in two separate cohorts: Cohort 1 will include participants with completely resected Stage IIC, IIIA (participants with one or more nodal metastasis greater than [>] 1 millimeter [mm] in diameter), or IIIB cutaneous melanoma, as defined by the American Joint Committee on Cancer (AJCC) Classification, Version 7; Cohort 2 will include participants with Stage IIIC cutaneous melanoma, as defined by this classification scheme. Within each cohort, participants will be randomized (1:1 ratio) to receive vemurafenib or matching placebo over a 52-week period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Melanoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
498 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1 Vemurafenib
Arm Type
Experimental
Arm Description
Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 milligrams (mg) twice daily, in 28-day cycles, for up to 52 weeks
Arm Title
Cohort 1 Placebo
Arm Type
Placebo Comparator
Arm Description
Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks
Arm Title
Cohort 2 Vemurafenib
Arm Type
Experimental
Arm Description
Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks
Arm Title
Cohort 2 Placebo
Arm Type
Placebo Comparator
Arm Description
Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks
Intervention Type
Drug
Intervention Name(s)
Vemurafenib
Other Intervention Name(s)
RO5185426/F17, Zelboraf
Intervention Description
4 tablets of vemurafenib 240 mg each (total 960 mg) were administered orally as per the schedule specified in the respective arm.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo matching to vemurafenib were administered orally as per the schedule specified in the respective arm.
Primary Outcome Measure Information:
Title
Disease-Free Survival (DFS) as Assessed Using Contrast-Enhanced Magnetic Resonance Imaging (MRI) or Contrast Enhanced Computed Tomography (CT)
Description
DFS was defined as the time from randomization until the date of the first local, regional, or distant melanoma recurrence, occurrence of new primary melanoma, or death from any cause.
Time Frame
From randomization until the date of the first local, regional, or distant melanoma recurrence, occurrence of new primary melanoma, or death from any cause (up to the April 17, 2017 data cut-off, approximately 4.5 years)
Secondary Outcome Measure Information:
Title
Distant Metastasis-Free Survival (DMFS) as Assessed Using Contrast-Enhanced MRI or Contrast Enhanced CT
Description
DMFS was defined as the time from randomization until the date of diagnosis of distant (i.e. non-locoregional) metastases or death from any cause.
Time Frame
From randomization until the date of diagnosis of distant (i.e., non-locoregional) metastases or death from any cause (up to the April 17, 2017 data cut-off, approximately 4.5 years)
Title
Overall Survival (OS)
Description
OS is defined as the time from randomization until the date of death from any cause.
Time Frame
From randomization until the date of death from any cause (up until 13-July-2018, approximately 6 years)
Title
Percentage of Participants With Adverse Events
Description
An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
Time Frame
From randomization up to study completion or discontinuation (up until 13-July-2018, approximately 6 years)
Title
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) 30-Item Quality of Life Questionnaire (QLQ-C30) Score
Description
European Organisation for Research and Treatment of Cancer 30-Item Quality of Life Questionnaire assesses 8 symptoms, function, financial difficulties, and a global health status/health-related quality of life (HRQoL). Most questions use a 4-point scale (1 'Not at all' to 4 'Very much';2 questions use a 7-point scale (1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. Higher scores for the function and HRQoL represent higher levels of functioning and HRQoL, higher scores for the symptom represent higher levels of symptoms/problems, higher score for financial difficulty represent higher level of perceived financial burden of treatment. Changes of 5-10 points are considered to represent a minimally important difference to participants. A positive value means an increase, and negative value means a decrease in score at the indicated time-point relative to the score at baseline (Cycle 1 Day 1).
Time Frame
Day 1, Day 8, Day 15, Day 22 of Cycle 1;Day 1, Day 15 of Cycle 2;Day 1 Cycles 3-13;end of treatment(up to 13 months);every 13 weeks thereafter until recurrence or occurrence of a new primary melanoma (up to 17-Apr-17 data cut-off,approximately 4.5 years)
Title
Plasma Concentration of Vemurafenib
Time Frame
Pre-morning dose (0 hour [hr]) and 1 to 4 hrs post-dose on Days 1, 8, 15, and 22 of Cycle 1; pre-morning dose (0 hr) on Days 1 and 15 of Cycle 2; pre-morning dose (0 hr) on Day 1 of Cycles 3-13; at end of treatment (up to 13 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically confirmed melanoma of cutaneous origin Participants with BRAFV600 mutation-positive, cutaneous melanoma (either pathologic Stage IIC or Stage III according to AJCC Staging Criteria version 7 that has been completely resected BRAF V600 mutation status of the current primary tumor or involved lymph node determined to be positive using the cobas BRAF V600 mutation test Surgically rendered free of disease within 90 days of randomization Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Life expectancy of at least 5 years Fully recovered from the effects of any major surgery or significant traumatic injury prior to the first dose of study treatment Adequate hematologic, hepatic, and renal function Exclusion Criteria: History of any systemic or local therapy (e.g., chemotherapy, biologic or targeted therapy, hormonal therapy, or photodynamic therapy) for the treatment or prevention of melanoma, including interferon alpha-2b and pegylated interferon alpha-2b History of limb perfusion therapy History of radiotherapy for the treatment of melanoma Invasive malignancy other than melanoma at the time of enrollment or within 5 years prior to first dose of study treatment Family history of inherited colon cancer syndromes Known personal history of >3 adenomatous colorectal polyps or a personal history of adenomatous colorectal polyp(s) >2 centimeters (cm) in size History of or current clinical, radiographic, or pathologic evidence of in-transit metastases, satellite, or microsatellite lesions History of or current clinical, radiographic, or pathologic evidence of recurrent lymph node involvement after resection of a primary melanoma with lymph node involvement at any time in the past History of local and/or regional and/or distant melanoma recurrence History or current radiographic or pathologic evidence of distant metastases History of clinically significant cardiac or pulmonary dysfunction Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study treatment Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
UCLA Department of Medicine; Division of Hematology / Oncology
City
California City
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
Kaiser Permanente - Hayward
City
Hayward
State/Province
California
ZIP/Postal Code
94545
Country
United States
Facility Name
UCLA Hematology Oncology - Irvine
City
Irvine
State/Province
California
ZIP/Postal Code
92604
Country
United States
Facility Name
UCSD Moores Cancer Center
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Facility Name
The Angeles Clinic and Research Institute - W LA Office
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Facility Name
Cancer Center Of Santa Barbara; Network Clinical Research Specialist
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
TRIO-US Network Administration; Network Clinical Research Specialist
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
Kaiser Foundation Hospital - Oakland (W. MacArthur)
City
Oakland
State/Province
California
ZIP/Postal Code
94611
Country
United States
Facility Name
Kaiser Permanente - Oakland
City
Oakland
State/Province
California
ZIP/Postal Code
94611
Country
United States
Facility Name
UCLA Healthcare/Pasadena Oncology
City
Pasadena
State/Province
California
ZIP/Postal Code
91105
Country
United States
Facility Name
Kaiser Permanente - Roseville
City
Roseville
State/Province
California
ZIP/Postal Code
95661
Country
United States
Facility Name
Kaiser Permanente Sacramento Medical Center
City
Sacramento
State/Province
California
ZIP/Postal Code
95814
Country
United States
Facility Name
Kaiser Permanente
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
Facility Name
K. Permanente - San Jose
City
San Jose
State/Province
California
ZIP/Postal Code
95119
Country
United States
Facility Name
Coastal Integrative Cancer Care
City
San Luis Obispo
State/Province
California
ZIP/Postal Code
93401
Country
United States
Facility Name
Kaiser Permanente - Santa Clara
City
Santa Clara
State/Province
California
ZIP/Postal Code
95051
Country
United States
Facility Name
Kaiser Permanente - South San Francisco
City
South San Francisco
State/Province
California
ZIP/Postal Code
94080
Country
United States
Facility Name
Stanford University School of Medicine; Stanford Hospital Pharmacy
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Facility Name
UCLA Cancer Center Hema/Oncol
City
Valencia
State/Province
California
ZIP/Postal Code
91355
Country
United States
Facility Name
Kaiser Permanente - Vallejo
City
Vallejo
State/Province
California
ZIP/Postal Code
94589
Country
United States
Facility Name
Kaiser Permanente - Walnut Creek
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94596
Country
United States
Facility Name
UCLA Hematology Oncology - Westlake
City
Westlake Village
State/Province
California
ZIP/Postal Code
91361
Country
United States
Facility Name
University Of Colorado
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
St. Mary's Hospital Regional Cancer Center
City
Grand Junction
State/Province
Colorado
ZIP/Postal Code
81501
Country
United States
Facility Name
Florida Cancer Specialists - Broadway
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33901
Country
United States
Facility Name
Memorial Healthcare System
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
Facility Name
GulfCoast Oncology
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34232
Country
United States
Facility Name
Oncology Specialists, S.C.
City
Park Ridge
State/Province
Illinois
ZIP/Postal Code
60068
Country
United States
Facility Name
Indiana University Health; Goshen Center for Cancer Care
City
Goshen
State/Province
Indiana
ZIP/Postal Code
46526
Country
United States
Facility Name
Indiana University Department of Medicine; Division of Infectious Diseases
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
U of L - Physicians Pulmonology; Dept of Neuroradiology and Dept of Diagnostic Radiology
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Name
Barbara Ann Karmanos Cancer Institute
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
St. Luke's Hospital
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64111
Country
United States
Facility Name
University of Kansas Medical Center; Cancer Center
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64131
Country
United States
Facility Name
Washington University; Dept of Medicine/Div of Medical Oncology
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Atlantic Health Systems; Pediatrics
City
Randolph
State/Province
New Jersey
ZIP/Postal Code
07869
Country
United States
Facility Name
New York University Medical Center PRIME; NYU Clinical Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Facility Name
Duke University Medical Center; Oncology
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
University of Pennsylvania Health System
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
MUSC Hollings Cancer Center/cannon Park Place; Attn: Tamara Saunders
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
West Clinic
City
Germantown
State/Province
Tennessee
ZIP/Postal Code
38138
Country
United States
Facility Name
Tennessee Oncology PLLC - Nashville (20th Ave)
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Facility Name
MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Mary Babb Randolph Cancer Center
City
Morgantown
State/Province
West Virginia
ZIP/Postal Code
26506
Country
United States
Facility Name
Fundación CIDEA
City
Buenos Aires
ZIP/Postal Code
C1425DTG
Country
Argentina
Facility Name
Instituto Medico Especializado Alexander Fleming
City
Ciudad Autonoma Buenos Aires
ZIP/Postal Code
1426
Country
Argentina
Facility Name
Hospital Britanico de Buenos Aires
City
Ciudad Autonoma Buenos Aires
ZIP/Postal Code
C1284AEB
Country
Argentina
Facility Name
Hospital Universitario Austral
City
Derqui-Pilar
ZIP/Postal Code
B1629ODT
Country
Argentina
Facility Name
Centro de Investigacion Pergamino SA
City
Pergamino
ZIP/Postal Code
B2700CPM
Country
Argentina
Facility Name
Instituto de Oncología de Rosario
City
Rosario
ZIP/Postal Code
S2000KZE
Country
Argentina
Facility Name
ISIS Clinica Especializada
City
Santa Fe
ZIP/Postal Code
S3000
Country
Argentina
Facility Name
Chris O'Brien Lifehouse
City
Camperdown
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
Facility Name
Melanoma Institute Australia
City
North Sydney
State/Province
New South Wales
ZIP/Postal Code
2060
Country
Australia
Facility Name
Calvary Mater Newcastle
City
Waratah
State/Province
New South Wales
ZIP/Postal Code
2298
Country
Australia
Facility Name
Border Medical Oncology
City
Wodonga
State/Province
New South Wales
ZIP/Postal Code
3690
Country
Australia
Facility Name
Southern Medical Day Care Centre
City
Wollongong
State/Province
New South Wales
ZIP/Postal Code
2500
Country
Australia
Facility Name
Cairns Base Hospital
City
Cairns
State/Province
Queensland
ZIP/Postal Code
4870
Country
Australia
Facility Name
The Townsville Hospital; Townsville Cancer Centre
City
Townsville
State/Province
Queensland
ZIP/Postal Code
4812
Country
Australia
Facility Name
Royal Adelaide Hospital; Hepatology
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Facility Name
Queen Elizabeth Hospital
City
Woodville
State/Province
South Australia
ZIP/Postal Code
5011
Country
Australia
Facility Name
Launceston General Hospital; Gastroenterology Research
City
Launceston
State/Province
Tasmania
ZIP/Postal Code
7250
Country
Australia
Facility Name
Box Hill Hospital
City
Box Hill
State/Province
Victoria
ZIP/Postal Code
3128
Country
Australia
Facility Name
Peninsula Oncology Centre; Frankston Private
City
Frankston
State/Province
Victoria
ZIP/Postal Code
3199
Country
Australia
Facility Name
Peter Maccallum Cancer Centre
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3000
Country
Australia
Facility Name
Alfred Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3004
Country
Australia
Facility Name
Fiona Stanley Hospital
City
Murdoch
State/Province
Western Australia
ZIP/Postal Code
6150
Country
Australia
Facility Name
Medizinische Universität Innsbruck
City
Innsbruck
ZIP/Postal Code
6020
Country
Austria
Facility Name
Klinikum Wels-Grieskirchen
City
Wels
ZIP/Postal Code
4600
Country
Austria
Facility Name
Krankenanstalt Rudolfstiftung Wien
City
Wien
ZIP/Postal Code
1030
Country
Austria
Facility Name
Medizinische Universität Wien
City
Wien
ZIP/Postal Code
1090
Country
Austria
Facility Name
ZNA Middelheim
City
Antwerpen
ZIP/Postal Code
2020
Country
Belgium
Facility Name
Institut Jules Bordet
City
Brussels
ZIP/Postal Code
1000
Country
Belgium
Facility Name
UZ Antwerpen
City
Edegem
ZIP/Postal Code
2650
Country
Belgium
Facility Name
UZ Gent
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
Jessa Zkh (Campus Virga Jesse)
City
Hasselt
ZIP/Postal Code
3500
Country
Belgium
Facility Name
AZ Groeninge, Apotheek
City
Kortrijk
ZIP/Postal Code
8500
Country
Belgium
Facility Name
Trymed Clinical Research
City
Belo Horizonte
State/Province
MG
ZIP/Postal Code
30150-281
Country
Brazil
Facility Name
Hospital de Caridade de Ijuí
City
Ijuí
State/Province
RO
ZIP/Postal Code
98700-000
Country
Brazil
Facility Name
CITO - Centro Integrado de Terapia Onco-Hematológica - Hospital da Cidade de Passo Fundo
City
Passo Fundo
State/Province
RS
ZIP/Postal Code
99010-260
Country
Brazil
Facility Name
Hospital das Clinicas - UFRGS
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90035-003
Country
Brazil
Facility Name
Clinica de Oncologia de Porto Alegre - CliniOnco
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90430-090
Country
Brazil
Facility Name
Hospital Sírio-Libanês
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
01308-050
Country
Brazil
Facility Name
BC Cancer Agency Vancouver Centre - PARENT; BC Cancer Agency
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 4E6
Country
Canada
Facility Name
Saint Boniface General Hospital; Section of Nephrology BG 007
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R2H 2A6
Country
Canada
Facility Name
Saint John Regional Hospital; Department of Oncology
City
Saint John
State/Province
New Brunswick
ZIP/Postal Code
E2L 4L2
Country
Canada
Facility Name
LHSC - Victoria Hospital; Department of Pediatrics
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 4G5
Country
Canada
Facility Name
The Ottawa Hospital Cancer Center; General Campus
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 1C4
Country
Canada
Facility Name
Toronto Sunnybrook Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N3M50
Country
Canada
Facility Name
Princess Margaret Hospital; Department of Med Oncology
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Facility Name
CHUM Hôpital Notre-Dame
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2L 4M1
Country
Canada
Facility Name
Mcgill University - Royal Victoria Hospital; Oncology
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3A 1A1
Country
Canada
Facility Name
CHUQ - Hôtel-Dieu de Québec
City
Ste-Foy
State/Province
Quebec
ZIP/Postal Code
G1V 4G2
Country
Canada
Facility Name
General Hospital Pula
City
Pula
ZIP/Postal Code
52100
Country
Croatia
Facility Name
General Hospital Varazdin
City
Varazdin
ZIP/Postal Code
42000
Country
Croatia
Facility Name
Clinical Hospital Center Sestre Milosrdnice
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Facility Name
Clinical Hospital Centre Zagreb
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Facility Name
Masarykuv onkologicky ustav
City
Brno
ZIP/Postal Code
656 53
Country
Czechia
Facility Name
Fakultni nemocnice Hradec Kralove
City
Hradec Kralove
ZIP/Postal Code
500 05
Country
Czechia
Facility Name
Fakultní nemocnice Olomouc
City
Olomouc
ZIP/Postal Code
775 20
Country
Czechia
Facility Name
Fakultni nemocnice Ostrava
City
Ostrava - Poruba
ZIP/Postal Code
708 52
Country
Czechia
Facility Name
Nemocnice Na Bulovce
City
Prague
ZIP/Postal Code
180 01
Country
Czechia
Facility Name
Vseobecna fakultni nemocnice v Praze
City
Praha 2
ZIP/Postal Code
128 08
Country
Czechia
Facility Name
Fakultni nemocnice Kralovske Vinohrady
City
Praha
ZIP/Postal Code
100 34
Country
Czechia
Facility Name
East Tallinn Central Hospital; Clinic of Internal Medicine
City
Tallinn
ZIP/Postal Code
11312
Country
Estonia
Facility Name
North Estonia Medical Centre Foundation
City
Tallinn
ZIP/Postal Code
13419
Country
Estonia
Facility Name
Tartu University Hospital; Clinic of Hematology and Oncology
City
Tartu
ZIP/Postal Code
50406
Country
Estonia
Facility Name
CHU Besançon - Hôpital Jean Minjoz
City
Besançon Cedex
ZIP/Postal Code
25030
Country
France
Facility Name
Groupe Hospitalier Saint André - Hôpital Saint André
City
Bordeaux
ZIP/Postal Code
33075
Country
France
Facility Name
Hôpital Ambroise Paré - Boulogne-Billancourt; Respiratory
City
Boulogne Billancourt
ZIP/Postal Code
92104
Country
France
Facility Name
Hopital Claude Huriez - CHU Lille
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
Hopital de la Timone
City
Marseille
ZIP/Postal Code
13005
Country
France
Facility Name
CHU NANTES - Hôtel Dieu; Pharmacy
City
Nantes
ZIP/Postal Code
44093
Country
France
Facility Name
CHU Nice - Hopital de l'Archet 2
City
Nice
ZIP/Postal Code
06202
Country
France
Facility Name
Hôpital Saint-Louis
City
Paris
ZIP/Postal Code
75475
Country
France
Facility Name
Centre Hospitalier Lyon Sud
City
Pierre Benite
ZIP/Postal Code
69495
Country
France
Facility Name
CHU de Rouen Hopital; Service de Neurologie
City
Rouen
ZIP/Postal Code
76031
Country
France
Facility Name
CHU de Toulouse - Hôpital Larrey
City
Toulouse
ZIP/Postal Code
31059
Country
France
Facility Name
St. Josef-Hospital Universitaetsklinikum
City
Bochum
ZIP/Postal Code
44791
Country
Germany
Facility Name
Elbekliniken Buxtehude GmbH
City
Buxtehude
ZIP/Postal Code
21614
Country
Germany
Facility Name
Universitätsklinikum Essen
City
Essen
ZIP/Postal Code
45147
Country
Germany
Facility Name
Universitaetsklinikum Frankfurt
City
Frankfurt
ZIP/Postal Code
60528
Country
Germany
Facility Name
Universitätsklinikum Heidelberg
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
Facility Name
Universitaetsklinikum Schleswig-Holstein - Campus Kiel; Klinik fuer Allgemeine Innere Medizin
City
Kiel
ZIP/Postal Code
24105
Country
Germany
Facility Name
Universitätsklinikum Koeln
City
Koeln
ZIP/Postal Code
50937
Country
Germany
Facility Name
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz; Apotheke
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Facility Name
Klinikum Mannheim GmbH Universitätsklinikum
City
Mannheim
ZIP/Postal Code
68167
Country
Germany
Facility Name
Fachklinik Hornheide
City
Muenster
ZIP/Postal Code
48157
Country
Germany
Facility Name
Universitätsklinikum Tübingen
City
Tuebingen
ZIP/Postal Code
72076
Country
Germany
Facility Name
Universitätsklinikum Wurzburg
City
Würzburg
ZIP/Postal Code
97080
Country
Germany
Facility Name
Cork University Hospital
City
Cork
Country
Ireland
Facility Name
Mater Private Hospital
City
Dublin
ZIP/Postal Code
7
Country
Ireland
Facility Name
The Mater Misericordiae Hospital
City
Dublin
ZIP/Postal Code
7
Country
Ireland
Facility Name
University College Hospital
City
Galway
Country
Ireland
Facility Name
Soroka Medical Center
City
Beer Sheva
ZIP/Postal Code
8410101
Country
Israel
Facility Name
Rambam Health Care Campus
City
Haifa
ZIP/Postal Code
3109600
Country
Israel
Facility Name
Hadassah University Hospital - Ein Kerem
City
Jerusalem
ZIP/Postal Code
9112001
Country
Israel
Facility Name
Rabin Medical Center-Beilinson Campus
City
Petach Tikva
ZIP/Postal Code
4941492
Country
Israel
Facility Name
Chaim Sheba Medical Center
City
Ramat Gan
ZIP/Postal Code
5265601
Country
Israel
Facility Name
Tel-Aviv Sourasky Medical Center
City
Tel Aviv
ZIP/Postal Code
6423906
Country
Israel
Facility Name
Istituto Nazionale Tumori Fondazione G. Pascale
City
Napoli
State/Province
Campania
ZIP/Postal Code
80131
Country
Italy
Facility Name
Azienda Ospedaliera Universitaria Policlinico Tor Vergata
City
Roma
State/Province
Lazio
ZIP/Postal Code
00133
Country
Italy
Facility Name
Istituto Nazionale Tumori Regina Elena IRCCS
City
Roma
State/Province
Lazio
ZIP/Postal Code
00144
Country
Italy
Facility Name
IDI-Istituto Dermopatico dell'Immacolata IRCCS
City
Roma
State/Province
Lazio
ZIP/Postal Code
00167
Country
Italy
Facility Name
Istituto Nazionale per la Ricerca sul Cancro di Genova
City
Genova
State/Province
Liguria
ZIP/Postal Code
16132
Country
Italy
Facility Name
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
City
Bergamo
State/Province
Lombardia
ZIP/Postal Code
24127
Country
Italy
Facility Name
Asst Degli Spedali Civili Di Brescia
City
Brescia
State/Province
Lombardia
ZIP/Postal Code
25100
Country
Italy
Facility Name
Ospedale San Raffaele
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20132
Country
Italy
Facility Name
Istituto Europeo Di Oncologia
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20141
Country
Italy
Facility Name
IRCCS Istituto Clinico Humanitas; Farmacia
City
Rozzano
State/Province
Lombardia
ZIP/Postal Code
20089
Country
Italy
Facility Name
Istituto Tumori Giovanni Paolo II IRCSS; Ospedale Oncologico Bari
City
Bari
State/Province
Puglia
ZIP/Postal Code
70126
Country
Italy
Facility Name
A.O.U. Senese Policlinico Santa Maria Alle Scotte
City
Siena
State/Province
Toscana
ZIP/Postal Code
53100
Country
Italy
Facility Name
IOV - Istituto Oncologico Veneto IRCCS
City
Padova
State/Province
Veneto
ZIP/Postal Code
35128
Country
Italy
Facility Name
Centro Oncologico Belenus
City
Cuernavaca
ZIP/Postal Code
62290
Country
Mexico
Facility Name
Hospital Civil de Guadalajara Fray Antonio Alcalde
City
Guadalajara
ZIP/Postal Code
44280
Country
Mexico
Facility Name
Centro Regiomontano de Investigación Clínica
City
Monterrey
ZIP/Postal Code
64710
Country
Mexico
Facility Name
Sanatorio la Luz
City
Morelia
ZIP/Postal Code
58260
Country
Mexico
Facility Name
Universitair Medisch Centrum Groningen
City
Groningen
ZIP/Postal Code
9713 GZ
Country
Netherlands
Facility Name
Leids Universitair Medisch Centrum; Cardiology
City
Leiden
ZIP/Postal Code
2333 ZA
Country
Netherlands
Facility Name
Christchurch Hospital NZ
City
Christchurch
ZIP/Postal Code
8011
Country
New Zealand
Facility Name
Wellington Hospital
City
Wellington
ZIP/Postal Code
6012
Country
New Zealand
Facility Name
Stavanger Universitetssykehus, Helse Stavanger HF
City
Stavanger
ZIP/Postal Code
4011
Country
Norway
Facility Name
SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie
City
Olsztyn
ZIP/Postal Code
10-228
Country
Poland
Facility Name
Przychodnia Med-Polonia Sp. z o.o.
City
Poznan
ZIP/Postal Code
60-693
Country
Poland
Facility Name
Centrum Onkologii- Instytut; im. M.Skłodowskiej-Curie
City
Warszawa
ZIP/Postal Code
02-781
Country
Poland
Facility Name
Dolnoslaskie Centrum Onkologii
City
Wroclaw
ZIP/Postal Code
53-439
Country
Poland
Facility Name
IPO de Coimbra; Servico de Oncologia Medica
City
Coimbra
ZIP/Postal Code
3000-075
Country
Portugal
Facility Name
Hospital do Espirito Santo; Servico de Oncologia Medica
City
Evora
ZIP/Postal Code
7000-811
Country
Portugal
Facility Name
Hospital de Santa Maria; Servico de Oncologia Medica
City
Lisboa
ZIP/Postal Code
1649-035
Country
Portugal
Facility Name
IPO do Porto; Servico de Oncologia Medica
City
Porto
ZIP/Postal Code
4200-072
Country
Portugal
Facility Name
Moscow City Oncology Hospital #62
City
Moscovskaya Oblast
State/Province
Moskovskaja Oblast
ZIP/Postal Code
143423
Country
Russian Federation
Facility Name
Krasnodar City Oncology Center
City
Krasnodar
ZIP/Postal Code
350040
Country
Russian Federation
Facility Name
FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
City
Moscow
ZIP/Postal Code
115478
Country
Russian Federation
Facility Name
Scientific Research Oncology Institute named after N.N. Petrov
City
St. Petersburg
ZIP/Postal Code
197758
Country
Russian Federation
Facility Name
Institute of Oncology and Radiology of Serbia
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Facility Name
Military Medical Academy
City
Belgrade
ZIP/Postal Code
11040
Country
Serbia
Facility Name
Clinical Center Bezanijska Kosa
City
Belgrade
ZIP/Postal Code
11070
Country
Serbia
Facility Name
Institute for oncology of Vojvodina
City
Sremska Kamenica
ZIP/Postal Code
21204
Country
Serbia
Facility Name
GVI Rondebosch Oncology Centre
City
Cape Town
ZIP/Postal Code
7700
Country
South Africa
Facility Name
Mary Potter Oncology Centre
City
Groenkloof
ZIP/Postal Code
0181
Country
South Africa
Facility Name
Groote Schuur Hospital Radiation Oncology Department; Department of Radiation Oncology
City
Observatory
ZIP/Postal Code
7925
Country
South Africa
Facility Name
University of Pretoria Oncology Department
City
Pretoria
ZIP/Postal Code
0001
Country
South Africa
Facility Name
Sandton Oncology Medical Group
City
Sandton
ZIP/Postal Code
2196
Country
South Africa
Facility Name
Hospital Clinico Universitario de Santiago
City
Santiago de Compostela
State/Province
LA Coruña
ZIP/Postal Code
15706
Country
Spain
Facility Name
Hospital Costa del Sol; Servicio de Oncologia
City
Marbella
State/Province
Malaga
ZIP/Postal Code
29600
Country
Spain
Facility Name
Hospital de la Santa Creu; i Sant Pau
City
Barcelona
ZIP/Postal Code
08025
Country
Spain
Facility Name
Institut Catala d Oncologia Hospital Duran i Reynals
City
Barcelona
ZIP/Postal Code
08908
Country
Spain
Facility Name
Hospital General Universitario Gregorio Marañon
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Facility Name
Hospital Universitari i Politecnic La Fe
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Facility Name
Länssjukhuset Ryhov
City
Jönköping
ZIP/Postal Code
551 85
Country
Sweden
Facility Name
Norrlands Universitetssjukhus
City
Umea
ZIP/Postal Code
901 850
Country
Sweden
Facility Name
Centrallasarettet Växjö
City
Växjö
ZIP/Postal Code
351 85
Country
Sweden
Facility Name
CHUV; Departement d'Oncologie
City
Lausanne
ZIP/Postal Code
1011
Country
Switzerland
Facility Name
CI Dnipropetrovsk CMCH 4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU
City
Dnipropetrovsk
ZIP/Postal Code
49102
Country
Ukraine
Facility Name
Lviv State Oncological Regional Treatment and Diagnostic Center
City
Lviv
ZIP/Postal Code
79031
Country
Ukraine
Facility Name
Bristol Haematology and Oncology Centre
City
Bristol
ZIP/Postal Code
BS2 8ED
Country
United Kingdom
Facility Name
Addenbrooke's Hospital
City
Cambridge
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom
Facility Name
Velindre Cancer Centre
City
Cardiff
ZIP/Postal Code
CF14 2TL
Country
United Kingdom
Facility Name
Western General Hospital
City
Edinburgh
ZIP/Postal Code
EH4 2XU
Country
United Kingdom
Facility Name
Queen Elizabeth Hospital
City
Kings Lynn
ZIP/Postal Code
PE30 4ET
Country
United Kingdom
Facility Name
Guys and St Thomas NHS Foundation Trust, Guys Hospital
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Facility Name
Nottingham University Hospitals City Campus
City
Nottingham
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
Facility Name
Churchill Hospital
City
Oxford
ZIP/Postal Code
OX3 7LJ
Country
United Kingdom
Facility Name
Royal Cornwall Hospital
City
Truro
ZIP/Postal Code
TR1 3LQ
Country
United Kingdom
Facility Name
New Cross Hospital
City
Wolverhampton
ZIP/Postal Code
WV10 0QP
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
31912791
Citation
Ascierto PA, Lewis KD, Di Giacomo AM, Demidov L, Mandala M, Bondarenko I, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Simmons B, Ye C, Hooper G, Wongchenko MJ, Goodman GR, Yan Y, Schadendorf D. Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib. Ann Oncol. 2020 Jan;31(1):153-159. doi: 10.1016/j.annonc.2019.10.002.
Results Reference
derived
PubMed Identifier
29477665
Citation
Maio M, Lewis K, Demidov L, Mandala M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21. Erratum In: Lancet Oncol. 2018 Apr;19(4):e184.
Results Reference
derived

Learn more about this trial

A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma

We'll reach out to this number within 24 hrs